What is Abivax?
Founded in 2013, Abivax operates at the intersection of immunology and drug discovery. The company is dedicated to mobilizing the body's natural immune machinery to address high-unmet medical needs, including autoimmune diseases, viral infections, and oncology. By leveraging a proprietary platform, Abivax aims to transform the standard of care for patients suffering from chronic inflammatory disorders. Its strategic focus on clinical-stage development has established it as a key player in the European biotech ecosystem, attracting institutional backing from specialized healthcare investors and government-backed innovation funds.
How much funding has Abivax raised?
Abivax has raised a total of $67M across 3 funding rounds:
Debt
$436K
Debt
$17.6M
Other Financing Round
$49M
Debt (2017): $436K with participation from Region Occitanie and Bpifrance
Debt (2020): $17.6M led by Kreos Capital
Other Financing Round (2022): $49M supported by Tcgx and Venrock Healthcare Capital Partners
Key Investors in Abivax
Bpifrance
A French public investment bank that supports companies at every stage of their development through credit, guarantees, and equity financing.
Kreos Capital
A London-based investment firm specializing in growth debt and providing strategic financial solutions to high-growth companies.
Tcgx
A venture capital firm focused on supporting innovative life sciences companies through strategic capital and industry expertise.
What's next for Abivax?
Following this major strategic investment, Abivax is poised to scale its clinical operations and advance its lead candidates through pivotal trials. The capital will likely be deployed to bolster research and development infrastructure, ensuring the company maintains its competitive edge in the rapidly evolving immunology market. As the firm transitions into more advanced clinical phases, the focus will shift toward regulatory milestones and potential commercialization strategies. Investors are closely monitoring the company's ability to translate its scientific breakthroughs into tangible patient outcomes, which will be essential for long-term value creation and future market expansion.
See full Abivax company page
